IGFBP5 Regulates Adhesion-Driven Bortezomib Resistance in Multiple Myeloma
Researchers identified IGFBP5 as a negative regulator of adhesion-mediated bortezomib resistance in multiple myeloma that modulates FAK/Src signaling.
Researchers identified IGFBP5 as a negative regulator of adhesion-mediated bortezomib resistance in multiple myeloma that modulates FAK/Src signaling.
A retrospective study reveals that frontline daratumumab, lenalidomide, and dexamethasone provided durable disease control in transplant-ineligible multiple myeloma patients older ...
A retrospective service evaluation found that implementing an electronic medical record and tailored case report form substantially increased complete documentation ...
A 2026 narrative review synthesizes evidence that inflammatory blood ratios, endothelial scores, and CAR-T-specific tools can stratify outcomes in hematologic ...
An adjusted cross-trial analysis found teclistamab plus daratumumab was associated with significantly longer progression-free and overall survival and deeper responses ...
The 25th International Cancer Imaging Society Meeting proceedings describe MRI biomarkers, structured reporting systems, and quantitative imaging tools that predict ...
A retrospective single-laboratory study of 267 bone marrow samples found that CD20 expression on plasma cells was more often retained ...
A Chinese case report documents an exceptionally rare presentation of Waldenström macroglobulinemia, in which an osteolytic lumbar vertebral fracture was ...
A new review maps how 3D bone marrow models, from spheroids to bioprinted and organ-on-chip systems, are being used to ...
Bone marrow stromal cells drive interleukin-6-mediated metabolic reprogramming and bortezomib resistance in multiple myeloma, a new open-access study reports.
A bioinformatic and preliminary experimental study identifies PTGS1, CA1, and SYK as prognostic genes in multiple myeloma and explores, without ...
A new review synthesizes the clinical evidence, toxicity profiles and resistance mechanisms behind six FDA-approved antibody-drug conjugates for blood cancers.
A case report describes a 64-year-old woman with multiple myeloma and an SCN5A overlap channelopathy who underwent autologous stem cell ...
A new review in Blood Research details how rare morphological and immunophenotypic variants of plasma cell neoplasms mimic lymphomas, carcinomas, ...
A retrospective cohort study of 100 patients finds that moderately severe kidney impairment at multiple myeloma diagnosis independently predicts long-term ...
An automated deep learning pipeline measured skeletal muscle and fat with high agreement from same-day whole-body MRI and low-dose PET/CT ...
A prospective single-center observational study found that patient-reported physical and functional burden after CAR T-cell therapy peaked during hospitalization and ...
A new mass spectrometry assay identifies patient-specific M-protein peptides in plasma without sequencing, showing generally concordant longitudinal trends with conventional ...
A retrospective study of 128 multiple myeloma patients links distinct CRS symptom profiles to onset timing, severity and duration after ...
A new editorial argues that extracellular vesicles both drive tumor adaptation and drug resistance and offer promising platforms for antitumor ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.